myCorporateResource.com

Skip to content

You are here: Industry

Compliance & Enforcement

Clinical Trials

Paul Hastings: Defendant’s Clinical Trial Found to Constitute Invalidating Public Use of Asserted Patents

Skip to content

Trending ..... Bowman v. Monsanto: SCOTUS on Self-Replicating Technologies (eg Seeds) ..... Broker-Dealer Faces FCPA, Travel Act and Securities Fraud Charges for Venezuelan Payments ..... NLRB's Employee Rights Poster Comes Down ..... Ralph Lauren Settles FCPA Charges ..... Kiobel: SCOTUS Sends Alien Tort Statute Packing ..... DoJ Cuts Corporate Plea Agreement Carve-Out ..... The SEC's Netflix Report: Regulation FD and Social Media ..... Changes to DGCL Would Simplify Back-end Mergers ..... SCOTUS Decides Comcast v Behrend ..... Standard Fire: SCOTUS on CAFA Amount in Controversy Rules ..... Kallick: DE Board Enjoined from Opposing Rival Slate ..... Advisers Falling Short on Custody Rule ..... How Bad Will it Be? That is Sequestration ..... Gabelli v. SEC: SCOTUS on Limitations Period for Federal Enforcement Actions ..... HIPAA Omnibus Rule ..... Final FATCA Regs ..... PPACA: Play or Pay ..... DOJ/SEC Issue FCPA Guidance .....

Defendant’s Clinical Trial Found to Constitute Invalidating Public Use of Asserted Patents

Paul Hastings
March 2, 2012

Clinical Trials

K&L Gates: FTC Rules that “Randomized Clinical Trial” Evidence is Necessary to Support Advertising Claims for Juice Beverage and Related Products

May 16, 2013 Clinical Trials

Holland & Knight: Controversial U.S. Medical Study Raises Informed Consent Questions

May 09, 2013 Clinical Trials

Sidley Austin: Draft Guidance on Dual Function Molecular Diagnostic Instruments Could Broaden FDA Reach into Non-Devices

April 12, 2013 Clinical Trials